Page last updated: 2024-08-16

ro 31-8220 and pep005

ro 31-8220 has been researched along with pep005 in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	1 (100.00)	2.80

Authors

Authors	Studies
Akdeniz, Ö; Erin, N; Isca, VMS; Rijo, P; Tavşan, E	1

Other Studies

1 other study(ies) available for ro 31-8220 and pep005

Article	Year
Rebound increases in chemokines by CXCR2 antagonist in breast cancer can be prevented by PKCδ and PKCε activators. Cytokine, 2021, Volume: 142 Topics: Alkanes; Animals; Bryostatins; Cell Line, Tumor; Cell Proliferation; Chemokine CXCL2; Chemokines; Cyclopropanes; Diterpenes; Enzyme Activators; Extracellular Signal-Regulated MAP Kinases; Female; Indoles; Mammary Neoplasms, Animal; Mice, Inbred BALB C; p38 Mitogen-Activated Protein Kinases; Phenylurea Compounds; Protein Kinase C-delta; Protein Kinase C-epsilon; Receptors, Interleukin-8B	2021

Article

Year

Rebound increases in chemokines by CXCR2 antagonist in breast cancer can be prevented by PKCδ and PKCε activators.

Cytokine, 2021, Volume: 142

Topics: Alkanes; Animals; Bryostatins; Cell Line, Tumor; Cell Proliferation; Chemokine CXCL2; Chemokines; Cyclopropanes; Diterpenes; Enzyme Activators; Extracellular Signal-Regulated MAP Kinases; Female; Indoles; Mammary Neoplasms, Animal; Mice, Inbred BALB C; p38 Mitogen-Activated Protein Kinases; Phenylurea Compounds; Protein Kinase C-delta; Protein Kinase C-epsilon; Receptors, Interleukin-8B

2021